The effect of prenatal antidepressant exposure on neonatal adaptation: A systematic review and meta-analysis

Journal of Clinical Psychiatry

Volumn 74, Issue 4, 2013, Pages

  Grigoriadis, Sophie ^a   VonderPorten, Emily H ^a   Mamisashvili, Lana ^a   Eady, Allison ^a   Tomlinson, George ^b,c,d   Dennis, Cindy Lee ^a   Koren, Gideon ^a,e,f   Steiner, Meir ^b,g,h,i   Mousmanis, Patricia ^j,k,l   Cheung, Amy ^a   Ross, Lori E ^a,m  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h ST JOSEPH S HOSPITAL   (Canada)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j Professional Development and Practice Support   (Canada)

^k York Central Hospital   (Canada)

^l MARKHAM STOUFFVILLE HOSPITAL   (Canada)

^m CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLONAZEPAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; VENLAFAXINE;

CENTRAL NERVOUS SYSTEM DISEASE; CHILD BEHAVIOR; CONVULSION; DISEASE ASSOCIATION; FEEDING DISORDER; FIRST TRIMESTER PREGNANCY; GASTROINTESTINAL DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPOGLYCEMIA; LETHARGY; META ANALYSIS; MUSCLE HYPOTONIA; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEONTALA ADAPTATION SYNDROME; NERVOUSNESS; NEWBORN; NEWBORN DISEASE; OUTCOME ASSESSMENT; PATHOLOGICAL CRYING; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PUERPERAL DEPRESSION; REVIEW; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; SEIZURE; SEROTONIN SYNDROME; SLEEP AROUSAL DISORDER; SYSTEMATIC REVIEW; TACHYPNEA; THIRD TRIMESTER PREGNANCY; TREMOR; WITHDRAWAL SYNDROME;

EID: 84876566191     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12r07967     Document Type: Review

References (49)

1. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depressionduring pregnancy: a report from the American Psychiatric Association andthe American College of Obstetricians and Gynecologists. Gen HospPsychiatry. 2009;31(5):403-413.
2. Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancyand the postpartum. Arch Women Ment Health. 2005;8(2):77-87.
3. Dietz PM, Williams SB, Callaghan WM, et al. Clinically identified maternaldepression before, during, and after pregnancies ending in live births.Am J Psychiatry. 2007;164(10):1515-1520.
4. Dennis CL, Allen K. Interventions (other than pharmacological, psychosocialor psychological) for treating antenatal depression. Cochrane Database SystRev. 2008;(4)
5. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnantwomen taking fluoxetine. N Engl J Med. 1996;335(14):1010-1015.
6. Koren G, Matsui D, Einarson A, et al. Is maternal use of selective serotoninreuptake inhibitors in the third trimester of pregnancy harmful to neonates?CMAJ. 2005;172(11):1457-1459.
7. Stiskal JA, Kulin N, Koren G, et al. Neonatal paroxetine withdrawalsyndrome. Arch Dis Child Fetal Neonatal Ed. 2001;84(2):F134-F135.
8. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndromeafter in utero exposure to selective serotonin reuptake inhibitors in terminfants. Arch Pediatr Adolesc Med. 2006;160(2):173-176.
9. Isbister GK, Dawson A, Whyte IM, et al. Neonatal paroxetine withdrawalsyndrome or actually serotonin syndrome? Arch Dis Child Fetal Neonatal Ed.2001;85(2):F147-F148.
10. Oberlander TF, Misri S, Fitzgerald CE, et al. Pharmacologic factors associatedwith transient neonatal symptoms following prenatal psychotropicmedication exposure. J Clin Psychiatry. 2004;65(2):230-237.
11. Lattimore KA, Donn SM, Kaciroti N, et al. Selective serotonin reuptakeinhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: A meta-analysis. J Perinatol. 2005;25(9):595-604.
12. Kallen B. Neonate characteristics after maternal use of antidepressants in latepregnancy. Arch Pediatr Adolesc Med. 2004;158(4):312-316.
13. Ross LE, Grigoriadis S, Mamisashvili L, et al. Quality assessment ofobservational studies in psychiatry: an example from perinatal psychiatricresearch. Int J Methods Psychiatr Res. 2011;20(4):224-234.
14. von Elm E, Altman DG, Egger M, et al STROBE Initiative. TheStrengthening the Reporting of Observational Studies in Epidemiology(STROBE) statement: guidelines for reporting observational studies. Lancet.2007;370(9596):1453-1457.
15. Downs SH, Black N. The feasibility of creating a checklist for the assessmentof the methodological quality both of randomised and non-randomisedstudies of health care interventions. J Epidemiol Community Health.1998;52(6):377-384.
16. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) forassessing the quality of nonrandomized studies in meta-analyses. Departmentof Epidemiology and Community Medicine, University of Ottawa, Canada.Ottawa Hospital Research Institute Web site. http://www.ohri.ca/programs/clinical- epidemiology/oxford.htm. Accessed November 7, 2012.
17. Guyatt GH, Oxman AD, Vist GE, et al GRADE Working Group. GRADE: An emerging consensus on rating quality of evidence and strength ofrecommendations. BMJ. 2008;336(7650):924-926.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.1986;7(3):177-188.
19. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method oftesting and adjusting for publication bias in meta-analysis. Biometrics.2000;56(2):455-463.
20. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, et al. Assessingheterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods.2006;11(2):193-206.
21. Viechtbauer W. Conducting meta-analyses in R with the metafor package.Journal of Statistical Software. 2010;36(3):1-48. http://www.jstatsoft. org/v36/i03/Accessed November 21, 2012.
22. The R Project for Statistical Computing. R: A language and environmentfor statistical computing. R Foundation for Statistical Computing, Vienna,Austria. ISBN 3-900051-07-0. http://www.R-project.org/. Accessed October22, 2012.
23. Moher D, Liberati A, Tetzlaff J, et al PRISMA Group. Reprint - preferredreporting items for systematic reviews and meta-analyses: the PRISMAstatement. Phys Ther. 2009;89(9):873-880.
24. Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors andadverse pregnancy outcomes. Am J Obstet Gynecol. 2006;194(4):961-966. 10.1016/j.ajog.206.02.019
25. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor useduring pregnancy and newborn neurobehavior. Pediatrics.2004;113(2):368-375
26. Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimesterexposure to paroxetine. Arch Pediatr Adolesc Med. 2002;156(11):1129- 1132.
27. Laine K, Heikkinen T, Ekblad U, et al. Effects of exposure to selectiveserotonin reuptake inhibitors during pregnancy on serotonergic symptoms innewborns and cord blood monoamine and prolactin concentrations.Arch Gen Psychiatry. 2003;60(7):720-726.
28. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatalexposure to selective serotonin reuptake inhibitor antidepressants andmaternal depression using population-based linked health data. Arch GenPsychiatry. 2006;63(8):898-906.
29. Davis RL, Rubanowice D, McPhillips H, et al HMO Research NetworkCenter for Education, Research in Therapeutics. Risks of congenitalmalformations and perinatal events among infants exposed to antidepressantmedications during pregnancy. Pharmacoepidemiol Drug Saf. 2007;16(10):1086-1094.
30. Ferreira E, Carceller AM, Agogue C, et al. Effects of selective serotoninreuptake inhibitors and venlafaxine during pregnancy in term and pretermneonates. Pediatrics. 2007;119(1):52-59.
31. Boucher N, Bairam A, Beaulac-Baillargeon L. A new look at the neonate'sclinical presentation after in utero exposure to antidepressants in latepregnancy. J Clin Psychopharmacol. 2008;28(3):334-339.
32. Maschi S, Clavenna A, Campi R, et al. Neonatal outcome following pregnancyexposure to antidepressants: a prospective controlled cohort study. BJOG.2008;115(2):283-289.
33. Galbally M, Lewis AJ, Lum J, et al. Serotonin discontinuation syndromefollowing in utero exposure to antidepressant medication: prospectivecontrolled study. Aust N Z J Psychiatry. 2009;43(9):846-854.
34. Rampono J, Simmer K, Ilett KF, et al. Placental transfer of SSRI and SNRIantidepressants and effects on the neonate. Pharmacopsychiatry.2009;42(3): 95-100.
35. Hendrick V, Smith LM, Suri R, et al. Birth outcomes after prenatal exposureto antidepressant medication. Am J Obstet Gynecol. 2003;188(3):812-815.
36. Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn.J Clin Psychopharmacol. 1995;15(6):417-420.
37. Gentile S. Selective serotonin reuptake inhibitor exposure during earlypregnancy and the risk of birth defects. Acta Psychiatr Scand.2011;123(4):266-275.
38. Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressantsand normal milestone development at 6 and 19 months of age. Pediatrics.2010;125(3): e600-e608.
39. Einarson A, Choi J, Einarson TR, et al. Incidence of major malformations ininfants following antidepressant exposure in pregnancy: results of a largeprospective cohort study. Can J Psychiatry. 2009;54(4):242-246.
40. Finnegan LP, Connaughton JF Jr, Kron RE, et al. Neonatal abstinencesyndrome: assessment and management. Addict Dis. 1975;2(1-2):141-158.
41. Weinberg MK, Tronick EZ. The impact of maternal psychiatric illness oninfant development. J Clin Psychiatry. 1998;59(suppl 2):53-61.
42. Gentile S. On categorizing gestational, birth, and neonatal complicationsfollowing late pregnancy exposure to antidepressants: the prenatalantidepressant exposure syndrome. CNS Spectr. 2010;15(3):167-185.
43. Koren G. SSRIs in late pregnancy: the risk of neonatal respiratory distress andseizures. Acta Psychiatr Scand. 2011;123(4):318-319, author reply 318-319.
44. Occhiogrosso M, Omran SS, Altemus M. Persistent pulmonary hypertensionof the newborn and selective serotonin reuptake inhibitors: lessons fromclinical and translational studies. Am J Psychiatry. 2012;169(2):134-140.
45. Sie SD, Wennink JM, van Driel JJ, et al. Maternal use of SSRIs, SNRIs andNaSSAs: practical recommendations during pregnancy and lactation[published online ahead of print July 27, 2011]. Arch Dis Child Fetal NeonatalEd.
46. Oberlander TF, Bonaguro RJ, Misri S, et al. Infant serotonin transporter(SLC6A4) promoter genotype is associated with adverse neonatal outcomesafter prenatal exposure to serotonin reuptake inhibitor medications.Mol Psychiatry. 2008;13(1):65-73.
47. Safety Alerts for Human Medical Products. Effexor and Effexor XR(venlafaxine HCl). US Food and Drug Administration (FDA) Web site.http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm154975.htm. Updated June 19,2009. Accessed November 7, 2012.
48. Potential adverse effects of SSRIs and other anti-depressants on newborns-Health Canada Advisory 2004-08-09. Health Canada Web site. http://www.antidepressantsfacts.com/2004-08-09-HealthCan-SSRIs-newborns.htm. Accessed November 7, 2012.
49. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in uteroexposure to serotonin reuptake inhibitors: literature review and implicationsfor clinical applications. JAMA. 2005;293(19):2372-2383.